The aim of this study was bioinformatics and phylogenetic analysis for 5′ UTR region of NEUROPEPTIDEY (NPY) gene and its association with body weight and egg production traits in Fars native chickens. For this porpuse 200 blood samples were collected from Fars Native chickens Breeding Center (Shamsabad station). The whole genome DNA was extracted using salting out protocol. The promotor region was amplified by PCR and SNP genotyping was performed by RFLP method. The frequencies of alleles A and B were estimated as 0. 46 and 0. 54, respectively. The population was deviated from H-W equilibrium. Statistical analysis indicated that there is no significant association between NPY genotypes and studied traits (egg number, age at first laying, egg weight at 84 weeks and body weight at 12 weeks). The results of phylogenetic analysis showed that the sequences of the NPY gene of Fars native chickens has the most simalirity with EU447658. 1 and EU447659. 1 sequence information. Interstingly, there is NPY gene of quail in phylogenetic analysis which can show the key role of NPY gene for regulating the physiological process.

Background: NEUROPEPTIDE Y (NPY) is an endocrine peptide hormone that is produced by many parts of the bidy specially hypothalamus and has various physiological effects. Repeated intracerebroventricular (ICV) injections have shown NPY to be the most potent stimulator of feeding yet discovered. Chronic studies of many endocrine systems are frustrated by the lack of a reliable delivery sytem and the instability of many peptides. We have used transected cell line to model chronic over expression of NPY. To achieve the correct processing of NPY it was necessary ti use clonal endocrine cell line e.g, RIN 1056a. Material and Methods: Full length of NPY cDNA was isolated by PCR, cloned into the expression vector pCEP4 and transected into RIN 1056a cells. NPY gen expression was shown by total RNA extraction from transfected cells and Northern blotting, correct processing was also confirmed by reversed – phase FPLC and size exclusion chromatography. Since the syngeneic strains were not available for these cells, they had to be immunoisolated. Cells were micro- encapsulated in semipermiable PTFE hollow fibres (MWCO 500000) by resuspending freshly trypsinised cells at a concentration of 4x 107 cells/ml in 1% alginate and loaded into the fibres (internal diameter 1mm). The fibre was heat sealed approximately every 3mm and the alginate solidified by immersion in 0.05% Cac12 solution. Results: Individual 3mm sections were maintained in 1ml DMEM 10% FCS and retained their NPY screting activity for at least 28 days in vitro. Secreation of IR-NPY was measured by specific radioimmunoassay. Secretion of NPY was maintained for 28 days at approximately the same level with secretion maintained at 150 fmol/hour/fibre. Conclusion: Therefore we have successfully transected this cell line with NPY cDNA for the first time and measured the production and secretion of NPY from transected cell in high levels.

NEUROPEPTIDE Y (NPY) is a 36 amino acid peptide found throughout the central and peripheral nervous system of rat and human. NPY has been proposed to play an important role in satiety. The aim of this study was to produce cell lines that secrete high levels of bioactive NPY. For this purpose, the complementary DNA (cDNA) that encodes NPY was isolated by PCR. The cDNA was then cloned into pCEP4, to form pCEP4NPY. 6-23 cells were transfected with pCEP4NPY by electroporation. Transfected cells were selected by the addition of hygromycin B to the culture medium. Resistant colonies were picked and transferred to 96-well plates. The medium was tested for IR-NPY using a specific NPY radioimmunoassay (RIA). The IR-NPY secreted by the cells was characterized by sephadex G50 chromatography and reversed phase fast protein liquid chromatography (FPLC). It was found to co-elute with the synthetic standard in both cases. RNA was extracted from the cells and subjected to Northern blot analysis using labeled NPY cDNA as a probe. The cells were found to express high levels of NPY at mRNA levels.

Introduction: Over expression of selected peptide receptors in human tumors has been shown to represent clinically relevant targets for cancer diagnosis and therapy. The aim of this work was to investigate NEUROPEPTIDE Y (NPY) as a new radiopharmaceutical for diagnosis of breast cancer.Methods: A NEUROPEPTIDE Y analogues with Y1 receptor preference and agonistic properties was synthesized by solid phase method. Labeling with 99mTc was performed and yield of labeling, stability in human serum, receptor binding in cell surface with internalization in SK-N-MC cells, and biodistribution in normal rat were determined.Results: Peptide was synthesized and labeled with more than 95% purity. Radiolabeled peptide was stable in human serum and specifically binds and internalized in the cells with Y1 receptor (4h=12%). A rapid clearance from blood pool and urinary excretion were observed.Conclusion: Our results showed that this peptide can be considerate as a candidate for diagnosis of breast tumors.

Introduction: Over expression of selected peptide receptors in human tumors has been shown to represent clinically relevant targets for cancer diagnosis and therapy. The aim of this work was to investigate NEUROPEPTIDE Y (NPY) as a new radiopharmaceutical for diagnosis of breast cancer.Methods: A NEUROPEPTIDE Y analogues with Y1 receptor preference and agonistic properties was synthesized by solid phase method. After conjugation with diethylenetriaminepentaacetic acid (DTPA) labeling with 111In was performed. For labeled peptide, yield of labeling, stability in human serum, receptor binding in cell surface with internalization in SK-N-MC cells, and biodistribution in normal rat were determined.Results: Peptide was synthesized and labeled with more than 95% purity. Radiolabeled peptide was stable in human serum and specifically binds and internalized in the cells with Y1 receptor (4h = 22%). A rapid clearance from blood pool and urinary with hepatobiliary excretion were observed.Conclusion: Our results showed that this peptide can be considered as a candidate for diagnosis of breast tumors.

Background: To observe the relationship between Tumor Necrosis Factor-alpha (TNF-α ) and NEUROPEPTIDE Y (NPY) expression and neurological function score in epileptic children. Methods: Fifty-four epileptic children diagnosed and treated in Xuzhou Children's Hospital, China from Feb 2017 to Mar 2018 were collected and included in a research group (RG), while 30 healthy children who under-went physical examination at the same time were included in the control group (CG). ELISA was used to detect the expression of TNF-α and NPY in the serum of children in the two groups, and those before treatment were compared. The National Institute of Health stroke scale (NIHSS) and Hamilton Anxiety (HAMA) scores before and after treatment were observed, and Pearson correlation was used to analyze the relationship between the expression levels of TNF-α and NPY in the serum as well as NIHSS and HAMA scores. Results: The expression levels of TNF-α and NPY in the serum of children in the RG were significantly higher than those in the CG (P<0. 001). The expression level of TNF-α was positively correlated with the NIHSS and HAMA scores (r=0. 748, P<0. 001) (r=0. 772, P<0. 001). The expression level of NPY was positively correlated with the NIHSS and HAMA scores (r=0. 768, P<0. 001) (r=0. 643, P<0. 001). Conclusion: TNF-α and NPY are highly expressed in epileptic children and are positively correlated with neu-rological function score.